Clinical Research Directory
Browse clinical research sites, groups, and studies.
PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis
Sponsor: Henry Ford Health System
Summary
So this a Phase I study with primary objective to determine the feasibility and safety of combining post-transplant cyclophosphamide and urinary-derived human chorionic gonadotropin and epidermal growth factor (uhCG/EGF) as graft versus host disease prophylaxis in stem cell transplant with MMUDs Secondary objectives are to determine the incidence acute and chronic GVHD, progression-free survival , and overall survival
Official title: Post-transplant Cyclophosphamide and Urinary-derived Human Chorionic Gonadotropin and Epidermal Growth Factor (uhCG/EGF) as Graft Versus Host Disease Prophylaxis for Mismatched Unrelated Donor Transplantation
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
18
Start Date
2021-12-23
Completion Date
2028-11-30
Last Updated
2026-02-24
Healthy Volunteers
No
Conditions
Interventions
uhCG/EGF
PTCY for 2 doses on day +3 and +4 after stem cell transplant followed by uhCG/EGF subcutaneously on day +7, +9 and +11 post stem cell transplant
Locations (1)
Henry Ford Hospital
Detroit, Michigan, United States